378
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

ORCID Icon, , , , , , ORCID Icon, , , ORCID Icon, , , , , , ORCID Icon, , , , , ORCID Icon, , ORCID Icon, , , , , , , ORCID Icon, , , , ORCID Icon, , , , , , , , ORCID Icon, , , & ORCID Icon show all
Pages 142-149 | Received 17 Nov 2021, Accepted 28 Apr 2022, Published online: 17 May 2022
 

Abstract

Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18–86). Most frequent NACT regimens used were FLOT (65.4%), DCF (17.4%) and ECF (8.1%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2%, R0 resection rate 86.4%, and D2 dissection rate was 66.8%. Rate of pCR and near-CR (24%), and R0 resection (84%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1–154 months). Estimated median overall survival (OS) was 58.4months (95% CI: 35.2–85.7) and disease-free survival (DFS) was 50.7 months (95% CI: 25.4–75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68%). We still do not know which NACT regimen is the best choice for daily practice.  Clinicians should tailor treatment regimens according to patients’ multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethics approval

All procedures performed were in accordance with ethical standards of institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical committee approval was obtained from our institute with a number of: 09.2020.1108.

Author’s contributions

TB: Design, writing article and analyzing data, PFY: Editing and supervision of article. All other authors: Collecting data.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

No financial support was given.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.